Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBIT Margin (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of EBIT Margin readings, the most recent being 26.18% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 356.0% to 26.18% in Q4 2025 year-over-year; TTM through Dec 2025 was 21.64%, a 258.0% decrease, with the full-year FY2025 number at 21.64%, down 258.0% from a year prior.
  • EBIT Margin hit 26.18% in Q4 2025 for Neurocrine Biosciences, down from 30.07% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 273.5% in Q2 2022 to a low of 27.16% in Q1 2023.
  • Median EBIT Margin over the past 5 years was 22.18% (2021), compared with a mean of 29.24%.
  • Biggest five-year swings in EBIT Margin: soared 25176bps in 2022 and later crashed -25724bps in 2023.
  • Neurocrine Biosciences' EBIT Margin stood at 11.63% in 2021, then skyrocketed by 316bps to 25.1% in 2022, then increased by 16bps to 29.17% in 2023, then dropped by -22bps to 22.62% in 2024, then increased by 16bps to 26.18% in 2025.
  • The last three reported values for EBIT Margin were 26.18% (Q4 2025), 30.07% (Q3 2025), and 21.18% (Q2 2025) per Business Quant data.